Wisniewski Tomasz, Winiecki Janusz, Makarewicz Roman, Zekanowska Ewa
Department of Oncology and Brachytherapy, Nicolaus Copernicus University Collegium Medicum, Bydgoszcz, Poland.
J BUON. 2020 Jan-Feb;25(1):527-530.
To evaluate and compare plasma osteopontin (OPN, a candidate prostate cancer biomarker) levels in prostate cancer patients receiving radiotherapy or combined radiotherapy or hormone therapy.
OPN levels were determined by ELISA in 40 prostate cancer patients eligible for radiotherapy (n=18 radiotherapy alone, n=22 combined radiotherapy and hormone therapy) before the start of irradiation, during treatment, and one month after its completion.
OPN levels were significantly higher (p=0.02) in prostate cancer patients after receiving radiotherapy compared to baseline. In a subgroup analysis, there were no differences in OPN levels before and after treatment in patients undergoing radiotherapy alone, but OPN levels were significantly higher in patients after radiotherapy with hormone therapy compared to baseline (p=0.04) and in patients during radiotherapy compared to baseline (p=0.03).
Radiotherapy can increase plasma OPN concentrations in patients with prostate cancer, and radiotherapy may interact with hormone therapy to increase OPN concentrations. These differences suggest that OPN is worthy of further study as a predictive biomarker.
评估并比较接受放疗、放化疗联合激素治疗的前列腺癌患者血浆骨桥蛋白（OPN，一种潜在的前列腺癌生物标志物）水平。
采用酶联免疫吸附测定法（ELISA），对40例符合放疗条件的前列腺癌患者（其中18例仅接受放疗，22例接受放化疗联合激素治疗）在放疗开始前、治疗期间及治疗结束后1个月测定其OPN水平。
与基线相比，接受放疗后的前列腺癌患者OPN水平显著升高（p=0.02）。亚组分析显示，仅接受放疗的患者治疗前后OPN水平无差异，但接受放化疗联合激素治疗的患者放疗后OPN水平相比基线显著升高（p=0.04），且治疗期间相比基线也显著升高（p=0.03）。
放疗可使前列腺癌患者血浆OPN浓度升高，且放疗可能与激素治疗相互作用，进一步升高OPN浓度。这些差异表明，OPN作为一种预测性生物标志物值得进一步研究。
